RxDoctor Payments Data

Michele Shober, DO

Ophthalmology · New Castle, PANPI 1700814290

Payments from drug & device makers

$2,043in general payments, 2019–2025

Across 92 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$317
  • Sun Pharmaceutical Industries Inc.$300
  • AbbVie$236
  • Biotissue Holdings Inc.$217
  • Novartis$214
  • Bausch & Lomb Americas Inc.$181
  • plus $577 from 9 others

What the payments were for

  • Food & beverage$2,02599%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,043 in reported general payments places this provider in the 55th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$106,478
Medicare patients
597
Services billed
1,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine152$134,952
LumiganBimatoprost201$63,546
Cyclosporine122$58,076
XiidraLifitegrast42$32,200
TyrvayaVarenicline Tartrate20$22,418
RocklatanNetarsudil Mesylat/Latanoprost32$12,586
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol54$10,071
Travoprost37$6,294
Latanoprost824$5,891
Timolol Maleate212$3,313
CombiganBrimonidine Tartrate/Timolol11$3,126
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat191$2,842
Tobramycin-DexamethasoneTobramycin/Dexamethasone54$1,968
Prednisolone Acetate53$1,139
Acetazolamide31$980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$236$201,624364 claims
Bausch & Lomb Americas Inc.Xiidra$181$32,20042 claims
Oyster Point Pharma, Inc.Tyrvaya$156$22,41820 claims
Aerie Pharmaceuticals, Inc.Rocklatan$17$12,58632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in New Castle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →